Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,357.20
(
0.00%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
107.74
(
0.25%
)
Bitcoin
76,907.22
(
-0.65%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: wallstarb post# 84961

Monday, 10/12/2009 6:47:14 PM

Monday, October 12, 2009 6:47:14 PM

Post# of 257580

VNDA probrably spent near $200m over the last XX years developing [Iloperidone]…

How do you figure that? I would guess that VNDA’s development expenses have been a small fraction of your figure.

why wouldnt [VNDA] publish the revenue share?

This deal does not have revenue sharing, but rather royalties on sales. The royalty terms in these kinds of deals are rarely disclosed.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today